1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. GLUT

GLUT

Glucose transporter

GLUTs (Glucose transporters ) are proteins comprising 12 membrane-spanning regions. GLUTs transport glucose across the plasma membrane by means of a facilitated diffusion mechanism.

GLUT1 (SLC2A1), a uniporter protein, facilitates the transport of glucose across the plasma membranes of mammalian cells. GLUT2 (SLC2A2) is a transmembrane carrier protein that enables protein facilitated glucose movement across cell membranes. GLUT3 (SLC2A3), mainly present in the brain, has high affinity for glucose. GLUT3 facilitates the transport of glucose across the plasma membranes of mammalian cells. GLUT4 (SLC2A4) is found in the heart, skeletal muscle, adipose tissue, and brain. GLUT4 is an insulin-responsive glucose transporter.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-163726
    GLUT1/EGFR-IN-1
    Inhibitor 99.75%
    GLUT1/EGFR-IN-1 (compound H) is a potent inhibitor of GLUT1 and EGFR. GLUT1/EGFR-IN-1 can simultaneously act on the EGFR tyrosine kinase ATP-binding site and inhibit GLUT1-mediated energy metabolism, resulting in reductions in ATP, MMP, intra-cellular lactic acid, and EGFR nuclear transfer. GLUT1/EGFR-IN-1 can be used for nasopharyngeal carcinoma (NPC) and triple-negative breast cancer (TNBC) research.
    GLUT1/EGFR-IN-1
  • HY-182000
    Xanthine oxidase-IN-23
    Inhibitor
    Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type Xanthine oxidase inhibitor with an IC50 of 3.33 μM. Xanthine oxidase-IN-23 directly binds to XOD in a reversible mixed-type manner to inhibit its catalytic activity. Xanthine oxidase-IN-23 upregulates ABCG2 and downregulates GLUT9 to promote renal urate excretion. Xanthine oxidase-IN-23 reduces serum urate levels and improves renal function in hyperuricemic mice. Xanthine oxidase-IN-23 can be used in the research of hyperuricemia.
    Xanthine oxidase-IN-23
  • HY-155093
    GLUT1-IN-3
    Inhibitor
    GLUT1-IN-3 (Compd 4b), an investigational compound associated with type 1 glucose transporter deficiency syndrome, potently suppresses seizures.
    GLUT1-IN-3
  • HY-149802
    SLC26A3-IN-1
    SLC26A3-IN-1 is an inhibitor of anion exchanger protein SLC26A3 (IC50=340 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea.
    SLC26A3-IN-1
  • HY-N0479S
    Licarin B-d4
    Licarin B-d4 is the deuterium labeled Licarin B (HY-N0479). Licarin B, a nitric oxide production inhibitor extracted from the component of the seeds of Myristica fragrans, improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway.
    Licarin B-d<sub>4</sub>
  • HY-177903
    Triptolide-6-succinate-β-D-glucose
    Triptolide-6-succinate-β-D-glucose (Compound 2) is a glucose-conjugated derivative of Triptolide (HY-32735). Triptolide-6-succinate-β-D-glucose is a tumor-selective prodrug targeting glucose transporters ( GLUT). Triptolide-6-succinate-β-D-glucose can induce the degradation of the RPB subunit of RNA polymerase II. Triptolide-6-succinate-β-D-glucose inhibits the proliferation of HEK293T cells with an IC50 value of 268 nM. Triptolide-6-succinate-β-D-glucose can be used for the research of cancer, such as prostatic cancer.
    Triptolide-6-succinate-β-D-glucose
  • HY-180784
    Hypoglycemic agent 4
    Hypoglycemic agent 4 (Compound 5b) is a tetrahydroacridine derivative with orally active hypoglycemic activity. Hypoglycemic agent 4 has a good binding affinity for the key diabetic targets: DPP-IV, SGLT1, and GLUT2. Hypoglycemic agent 4 can inhibit glucose diffusion. Hypoglycemic agent 4 can reduce fasting blood sugar in Streptozotocin (HY-13753)-induced diabetic rats and its effect is comparable to Gliclazide (HY-B0753). Hypoglycemic agent 4 can be used for research of type 2 diabetes.
    Hypoglycemic agent 4
  • HY-151486
    GLUT1-IN-1
    Inhibitor
    GLUT1-IN-1 is a glucose transporter 1 (GLUT1) inhibitor and has a GLUT1-specific inactivation ability. GLUT1-IN-1 exhibits concentration-dependent cytotoxicity for HeLa, A549 and HepG2 cells with IC50 values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. GLUT1-IN-1 can be used for the research of photodynamic therapy (PDT) and severals cancer.
    GLUT1-IN-1
  • HY-183658
    URAT1/GLUT9-IN-3
    Inhibitor
    URAT1/GLUT9-IN-3 is an orally active URAT1/GLUT9 dual inhibitor with IC50 values of 4.01 and 1.60 μM. URAT1/GLUT9-IN-3 inhibits URAT1-mediated uric acid uptake and GLUT9-mediated uric acid transport, reducing renal urate reabsorption. URAT1/GLUT9-IN-3 reduces serum uric acid levels in hyperuricemic mice. URAT1/GLUT9-IN-3 can be used for the researches of gout and hyperuricemia.
    URAT1/GLUT9-IN-3
  • HY-176050
    Rapaglutin A
    Inhibitor
    Rapaglutin A is a glucose transporter (GLUT) inhibitor. Rapaglutin A is a pan-GLUT inhibitor of Class I isoforms GLUT1, GLUT3, and GLUT4 with an IC50 of 12 nM. Rapaglutin A has an inhibitory effect on A549 proliferation.
    Rapaglutin A
  • HY-175645
    NLRP3/URAT1-IN-1
    Inhibitor
    NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and URAT1 (IC50 = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC50 of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia.
    NLRP3/URAT1-IN-1
  • HY-170313
    GLUT-1-IN-4
    Inhibitor
    GLUT-1-IN-4 (Compound 13) is the p53 protein-dependent inhibitor for GLUT-1 glucose transporter. GLUT-1-IN-4 inhibits the proliferation of multiple cancer cells with IC50 in submicromolar levels. GLUT-1-IN-4 arrests the cell cycle, stimulates oxidative stress, and induces apoptosis.
    GLUT-1-IN-4
  • HY-167857S
    Glutathione Disulfide-13C4,15N2
    Glutathione Disulfide-13C4,15N2 is the 13C- and 15N-labeled (Rac)-Glutipyran (HY-167857). (Rac)-Glutipyran is a broad-spectrum GLUT inhibitor that targets both GLUT1 and GLUT3. (Rac)-Glutipyran inhibits glucose uptake and suppresses the growth of multiple cancer cells, significantly inhibiting PANC-1 cell growth (IC50=1.8 μM) and glucose uptake (IC50=0.13 μM).
    Glutathione Disulfide-<sup>13</sup>C<sub>4</sub>,<sup>15</sup>N<sub>2</sub>
  • HY-183543
    URAT1/GLUT9-IN-2
    Inhibitor
    URAT1/GLUT9-IN-2 (Compound 42) is a selective, orally active URAT1/GLUT9 inhibitor, with an IC50 of 2.81 μM against URAT1 and an IC50 of 12.53 μM against GLUT9. URAT1/GLUT9-IN-2 reduces serum uric acid levels and protects renal function. URAT1/GLUT9-IN-2 can be used in research related to hyperuricemia and hyperuricemic nephropathy.
    URAT1/GLUT9-IN-2
  • HY-161501
    3-Fluoro-evodiamine glucose
    Activator
    3-Fluoro-evodiamine glucose (Compound 8) is an evodiamine-glucose conjugate. 3-Fluoro-evodiamine glucose activates the expression of glucose transporter 1 (GLUT1), and inhibits topoisomerase I/II. 3-Fluoro-evodiamine glucose induces apoptosis and arrests the cell cycle at G2/M phase. 3-Fluoro-evodiamine glucose exhibits antitumor efficacy in vivo and in vitro, without significant toxicity.
    3-Fluoro-evodiamine glucose
  • HY-N0755R
    Rhoifolin (Standard)
    Activator
    Rhoifolin (Standard) is the analytical standard of Rhoifolin. This product is intended for research and analytical applications. Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines.
    Rhoifolin (Standard)
  • HY-18284
    AS1938909
    Inducer
    AS1938909 is a compound that inhibits SHIP2 activity. It can selectively inhibit SHIP2, increase Akt phosphorylation, and regulate glucose metabolism. Its effect is related to upregulating GLUT1 gene expression.
    AS1938909
  • HY-155034
    Antitumor agent-102
    Inhibitor
    Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562).
    Antitumor agent-102
  • HY-162132
    WZB117-PPG
    Inhibitor
    WZB117-PPG is a glucose transporter 1 (GLUT1) inhibitor with anticancer activity. WZB117-PPG has remarkable photolysis efficiency and cytotoxicity to cancer cells under visible light irradiation.
    WZB117-PPG
  • HY-128447R
    Allyl methyl sulfide (Standard)
    Activator
    Allyl methyl sulfide (Standard) is the analytical standard of Allyl methyl sulfide (HY-128447). This product is intended for research and analytical applications. Allyl methyl sulfide is an orally active organic sulfide. Allyl methyl sulfide is one of the main active ingredients in garlic volatile metabolites. Allyl methyl sulfide can be extracted from garlic. Allyl methyl sulfide enhances SOD activity, inhibits NF-κB signaling pathway, and upregulates pancreatic GLUT2 expression. Allyl methyl sulfide has significant antioxidant, anti-inflammatory and hypoglycemic activities. Allyl methyl sulfide can be used in the research of diabetes and its complications.
    Allyl methyl sulfide (Standard)
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.